Literature DB >> 11673030

Life-threatening adverse events of antiepileptic drugs.

S Arroyo1, A de la Morena.   

Abstract

Treating a patient with antiepileptic drugs (AEDs) may give rise to unexpected life-threatening adverse events. Despite extensive experimental and clinical testing to ensure safety, most AEDs on the market have been associated with cases of severe cutaneous reactions, serious hematological disorders, or hepatic failure. Most of these disorders emerge as idiosyncratic immune-mediated disease or are related to toxic metabolic products of the AEDs. Early diagnosis is the only means of reducing the harmful, potentially fatal effects of these reactions. A high degree of suspicion, knowledge of risk factors, and close physician-patient contact increases the likelihood of early diagnosis and treatment. When diagnosed, severe reactions must be fully documented and reported to health authorities. The very rare occurrence of life threatening events should not, in general, limit treatment decision-making. Future epidemiological, chemical, and genetic research might provide methods for ascertaining which patients are at risk, so undue exposure can be avoided.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673030     DOI: 10.1016/s0920-1211(01)00306-0

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  17 in total

1.  The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment.

Authors:  Andrew Lloyd; Emma McIntosh; Martin Price
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 2.  The Potential Therapeutic Capacity of Inhibiting the Brain Renin-Angiotensin System in the Treatment of Co-Morbid Conditions in Epilepsy.

Authors:  Natasha Ivanova; Jana Tchekalarova
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

3.  The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK.

Authors:  Agnes Benedict; Lara Verdian; Grant Maclaine
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 4.  Overtreatment in epilepsy: how it occurs and how it can be avoided.

Authors:  Emilio Perucca; Patrick Kwan
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Single Unprovoked Seizures.

Authors:  Susan T. Herman
Journal:  Curr Treat Options Neurol       Date:  2004-05       Impact factor: 3.598

6.  New prospects of mesenchymal stem cells for ameliorating temporal lobe epilepsy.

Authors:  Neveen A Salem; Marwa El-Shamarka; Yasser Khadrawy; Shaimaa El-Shebiney
Journal:  Inflammopharmacology       Date:  2018-02-22       Impact factor: 4.473

7.  Use and safety profile of antiepileptic drugs in Italy.

Authors:  M L Iorio; U Moretti; S Colcera; L Magro; I Meneghelli; D Motola; A L Rivolta; F Salvo; G P Velo
Journal:  Eur J Clin Pharmacol       Date:  2007-02-16       Impact factor: 2.953

Review 8.  The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions.

Authors:  Patricia T Illing; Anthony W Purcell; James McCluskey
Journal:  Immunogenetics       Date:  2017-07-10       Impact factor: 3.330

9.  Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects.

Authors:  Erik K St Louis
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

10.  Chronotolerance study of the antiepileptic drug valproic acid in mice.

Authors:  Wafa Ben-Cherif; Ichrak Dridi; Karim Aouam; Mossadok Ben-Attia; Alain Reinberg; Naceur A Boughattas
Journal:  J Circadian Rhythms       Date:  2012-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.